Millennium Management
EPRX

Millennium Management’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Millennium Management’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,000
Closed -$31.3K – 6504
2024
Q4 		$31.3K Buy
+10,000
New +$29.6K ﹤0.01% 5661

Other funds holding EPRX

SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Millennium Management's EPRX Position: Q1 2025 in Review

Millennium Management sold out of Eupraxia Pharmaceuticals (EPRX) in Q1 2025, closing a stake of 10,000 shares — an estimated $31.3K sold.

Millennium Management first reported a position in EPRX in Q4 2024 and held it in 1 quarter. The position peaked at $31.3K in Q4 2024. 11 funds tracked by Wall St. Rank hold EPRX as of Q1 2025.

  • Millennium Management reported no remaining Eupraxia Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Millennium Management sold 10,000 Eupraxia Pharmaceuticals shares in Q1 2025, an estimated $31.3K.
  • Millennium Management first reported a position in Eupraxia Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Millennium Management's Eupraxia Pharmaceuticals position peaked at $31.3K in Q4 2024.
  • 11 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q1 2025.

Based on Millennium Management's 13F filing for Q1 2025, filed 15 May 2025.